Literature Review

Parkinson’s death rate rising, reasons unclear


 

FROM NEUROLOGY

1.2 million patients by 2030

Reached for comment, James Beck, PhD, chief scientific officer for the Parkinson’s Foundation, said these findings are not surprising. “They are aligned with the work the Parkinson’s Foundation has done to show that the number of people with Parkinson’s disease has increased over time. We are working on an improved estimate of Parkinson’s disease incidence and predict that Parkinson’s disease will continue to rise as the population ages, so an increase in mortality rates would be expected,” Dr. Beck said.

He noted that much of the public health statistics regarding Parkinson’s disease are outdated and that the Parkinson’s Foundation has been partnering with others to update them.

“For instance, to calculate an accurate estimate of the prevalence of Parkinson’s disease, the Parkinson’s Foundation Prevalence Project was formed. The findings from this group demonstrated that the number of people living with Parkinson’s disease will rise to nearly 1.2 million by 2030, a substantial increase from the estimate of 930,000 for 2020,” Dr. Beck said.

“The overarching message is that more people are being diagnosed with Parkinson’s disease, not that more people are dying from the disease,” he added.

“Over the last 20 years, our understanding of Parkinson’s disease has changed and developed, so clinicians are more aware and better able to properly diagnose Parkinson’s disease. This could mean that the cause is likely due to an increase in diagnosis rates and better recognition of Parkinson’s disease, which would lead to higher rates of identifying Parkinson’s disease as a cause of death,” said Dr. Beck.

The study had no targeted funding. Dr. Bao and Dr. Beck have indicated no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Survey identifies clinicians’ unease with genetic testing
MDedge Neurology
Sublingual film well tolerated for Parkinson ‘off’ episodes
MDedge Neurology
Efforts target underrepresented populations in Parkinson’s disease genetic studies
MDedge Neurology
Study identifies pandemic-related stressor in Parkinson’s disease
MDedge Neurology
Apple devices identify early Parkinson’s disease
MDedge Neurology
Worsening motor function tied to post COVID syndrome in Parkinson’s disease
MDedge Neurology
Customized brain stimulation: New hope for severe depression
MDedge Neurology
Art therapy linked to slowed Parkinson’s progression
MDedge Neurology
Influenza tied to long-term increased risk for Parkinson’s disease
MDedge Neurology
FDA not recognizing efficacy of psychopharmacologic therapies
MDedge Neurology